Onco Wiki / Red flag

Frailty profile influencing MF/Sézary therapy selection: ECOG ≥3, OR (age ≥75 with G8 ≤14...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Red Flag Origin

Trigger Logic

{
  "any_of": [
    {
      "comparator": ">=",
      "finding": "ecog",
      "threshold": 3
    },
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "age",
          "threshold": 75
        },
        {
          "comparator": "<=",
          "finding": "g8_score",
          "threshold": 14
        }
      ]
    },
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "age",
          "threshold": 70
        },
        {
          "comparator": ">=",
          "finding": "charlson_score",
          "threshold": 3
        },
        {
          "comparator": "<",
          "finding": "albumin_g_dl",
          "threshold": 3.5
        }
      ]
    }
  ],
  "type": "composite_score"
}

Notes

MF/Sézary is typically chronic / indolent in early stages, allowing skin-directed approach (topical corticosteroids, mechlorethamine gel, bexarotene topical, narrowband UVB, PUVA) for stage IA-IIA regardless of age. Frail elderly with stage IIB+ or Sézary: low-dose oral MTX (10-25 mg weekly), IFN-α, or mogamulizumab — all well-tolerated. Avoid multi-agent gem-doxo / CHOP-like regimens in frail (no curative endpoint, considerable toxicity, marginal PFS gains). AlloHCT is the only curative modality but typically off-table for frail elderly.

Used By

No reverse references found in the YAML corpus.